安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AMGN 安进

盘前交易 02-13 08:18:06 EST

366.20

-0.38

-0.10%

盘前363.00

-0.68-0.19%

08:15 EST

最高370.88	最低365.06	成交量237.45万
今开366.66	昨收366.58	日振幅1.59%
总市值1,972亿	流通市值1,966亿	总股本5.38亿
成交额8.72亿	换手率0.44%	流通股本5.37亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AMGN","market":"US","secType":"STK","nameCN":"安进","latestPrice":366.2,"timestamp":1770930000000,"preClose":366.58,"halted":0,"volume":2374457,"hourTrading":{"tag":"盘前","latestPrice":363,"preClose":363.68,"latestTime":"08:15 EST","volume":954,"amount":346776.67224000004,"timestamp":1770988511469,"change":-0.68,"changeRate":-0.00187,"amplitude":0.009321},"delay":0,"changeRate":-0.0010366086529543224,"floatShares":536994627,"shares":538480671,"eps":14.23,"marketStatus":"盘前交易","change":-0.38,"latestTime":"02-13 08:18:06 EST","open":366.66,"high":370.88,"low":365.061,"amount":872012091.1561501,"amplitude":0.015874,"askPrice":366,"askSize":200,"bidPrice":362.18,"bidSize":110,"shortable":3,"etf":0,"ttmEps":14.23,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770993000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":423288000000,"exchange":"NASDAQ","adjPreClose":363.68,"dividendRate":0.026,"preHourTrading":{"tag":"盘前","latestPrice":363,"preClose":363.68,"latestTime":"08:15 EST","volume":954,"amount":346776.67224000004,"timestamp":1770988511469,"change":-0.68,"changeRate":-0.00187,"amplitude":0.009321},"postHourTrading":{"tag":"盘后","latestPrice":366.4,"preClose":366.2,"latestTime":"19:59 EST","volume":142090,"amount":52035450.6489,"timestamp":1770944373200,"change":0.2,"changeRate":0.000546,"amplitude":0.004915},"volumeRatio":0.6965489678599817,"optionData":{"bulkOrders":[{"symbol":"AMGN","call":true,"expireDate":1773979200000,"strike":"300.0","timestamp":1770929222690,"price":66.3,"volume":38000,"amount":251940000,"type":"-"},{"symbol":"AMGN","call":true,"expireDate":1773979200000,"strike":"290.0","timestamp":1770929222690,"price":79.65,"volume":20500,"amount":163282500,"type":"+"}]},"impliedVol":0.2512,"impliedVolPercentile":0.248},"requestUrl":"/m/hq/s/AMGN/wiki","defaultTab":"wiki","newsList":[{"id":"2610684644","title":"Argus上调安进目标价至400美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610684644","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610684644?lang=zh_cn&edition=full","pubTime":"2026-02-09 15:22","pubTimestamp":1770621743,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BJJMRZ35.SGD","LU1057294990.SGD","LU2242646821.SGD","BK4581","LU1983299246.USD","LU0109394709.USD","IE00BJT1NW94.SGD","BK4533","BK4588","LU0889565916.HKD","LU0289739699.SGD","IE00B4R5TH58.HKD","BK4139","LU0868494617.USD","BK4599","BK4534","LU1023059063.AUD","AMGN","IE00B2B36J28.USD","LU0122379950.USD","LU1571399168.USD","SG9999001440.SGD","LU0320765992.SGD","IE00BFTCPJ56.SGD","LU2242652126.USD","IE0002141913.USD","LU2112291526.USD","BK4566","IE0009355771.USD","BK4585","LU2468319806.SGD","LU2089984988.USD","LU0058720904.USD","LU1061106388.HKD"],"gpt_icon":0},{"id":"2609324007","title":"花旗上调安进目标价至345美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609324007","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609324007?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:27","pubTimestamp":1770280021,"startTime":"0","endTime":"0","summary":"花旗将安进的目标价从315美元上调至345美元，维持“中性”评级。(格隆汇)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260205/32000802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["AMGN"],"gpt_icon":0},{"id":"1129271059","title":"安进核心业务强劲增长，抵消减肥药上市延迟影响——市场快评","url":"https://stock-news.laohu8.com/highlight/detail?id=1129271059","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129271059?lang=zh_cn&edition=full","pubTime":"2026-02-05 03:58","pubTimestamp":1770235106,"startTime":"0","endTime":"0","summary":"尽管安进公司的新型减肥药物尚需进一步测试，但其核心产品正持续推动业绩增长。威廉·布莱尔分析师指出，虽然投资者目光聚焦于减肥疗法MariTide，但该药关键的第三阶段试验结果预计要到2027年才能揭晓。在此期间，降胆固醇药物瑞百安与哮喘治疗药Tezspire等核心产品正为短期增长提供动力。\n值得注意的是，安进发布的2026年初步营收指引超出市场预期，彰显出现有产品组合的强劲实力。尽管肥胖治疗领域竞争激烈，威廉·布莱尔仍维持\"跑赢大盘\"评级，认为该股未来仍存重要临床催化剂。当前安进股价涨幅达8.5%。\n（本文根据市场公开信息整理，不构成投资建议）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","BK4533","BK4566","SG9999001440.SGD","BK4585","LU0289739699.SGD","LU0109394709.USD","LU0868494617.USD","LU0889565916.HKD","BK4599","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU2468319806.SGD","AMGN","LU2242652126.USD","IE00B2B36J28.USD","LU2089984988.USD","BK4534","IE00BFTCPJ56.SGD","LU1571399168.USD","LU1023059063.AUD","LU0320765992.SGD","IE0002141913.USD","LU2112291526.USD","LU1057294990.SGD","LU0122379950.USD","BK4588","IE0009355771.USD","LU1061106388.HKD","LU1983299246.USD","BK4581","LU0058720904.USD","IE00B4R5TH58.HKD","BK4139"],"gpt_icon":0},{"id":"2608239559","title":"美股异动丨安进涨超5%创新高，Q4业绩及今年指引均超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2608239559","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608239559?lang=zh_cn&edition=full","pubTime":"2026-02-04 23:30","pubTimestamp":1770219008,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4139","BK4550","LU1023059063.AUD","LU0320765992.SGD","BK4566","BK4599","LU1061106388.HKD","LU0868494617.USD","UWM","IE0009355771.USD","LU0109394709.USD","IE0002141913.USD","LU2242652126.USD","MNQmain","IE00B2B36J28.USD","SG9999001440.SGD","LU2112291526.USD","RWM","LU0058720904.USD","TNA","LU0889565916.HKD","SRTY","LU2242646821.SGD","IE00BJT1NW94.SGD","LU2089984988.USD","BK4581","AMGN","04332","BK4535","IE00BFTCPJ56.SGD","TWM","LU1571399168.USD","LU1983299246.USD","BK4534","LU0289739699.SGD","LU1057294990.SGD","TZA","IE00B4R5TH58.HKD","LU0122379950.USD","IWO","BK4533","BK4588","BK4585","LU2468319806.SGD","IWN","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"1165129857","title":"异动解读 | 安进盘中大涨5.30%，2026年盈利预测乐观及业绩超预期提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1165129857","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165129857?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:52","pubTimestamp":1770216769,"startTime":"0","endTime":"0","summary":"安进今日盘中大涨5.30%，引起了市场的广泛关注。消息面上，安进公司发布了乐观的2026年盈利预测，其预计年度调整后每股收益介于21.60美元至23美元之间，高于分析师平均预期的22.09美元。在此利好消息推动下，多家券商纷纷上调了安进的目标价，包括Leerink Partners将目标价从305美元上调至355美元，TD Cowen将目标价从389美元上调至420美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AMGN"],"gpt_icon":0},{"id":"2608633846","title":"安进Q4业绩超预期，继续推进新一代减肥药临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2608633846","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608633846?lang=zh_cn&edition=full","pubTime":"2026-02-04 10:18","pubTimestamp":1770171504,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1057294990.SGD","IE00B4R5TH58.HKD","LU2089984988.USD","BK4585","LU1023059063.AUD","BK4599","LU0289739699.SGD","LU1983299246.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","BK4581","LU2112291526.USD","BK4534","IE0009355771.USD","BK4533","LU2242652126.USD","BK4566","BK4588","IE00BJJMRZ35.SGD","LU1061106388.HKD","IE00B2B36J28.USD","AMGN","LU0109394709.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","LU0889565916.HKD","LU0058720904.USD","LU2242646821.SGD","IE0002141913.USD","BK4139","LU1571399168.USD","SG9999001440.SGD","LU2468319806.SGD","LU0868494617.USD"],"gpt_icon":0},{"id":"2608789416","title":"数十亿打水漂，安进退货自免 FIC 单抗","url":"https://stock-news.laohu8.com/highlight/detail?id=2608789416","media":"药研界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608789416?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:10","pubTimestamp":1770023451,"startTime":"0","endTime":"0","summary":"近日，在支付了 4 亿美元首付款后，安进终止了与协和麒麟就Rocatinlimab 达成的合作。根据 Insight 数据库，Rocatinlimab 共启动了9 项 III 期临床，其中 8 项的适应症都为特应性皮炎。2025 年11 月，《The Lancet》杂志发表了该产品用于中重度特应性皮炎的两项III 期ROCKET-IGNITE 和 ROCKET-HORIZON 研究结果。这两项研究共纳入近 1500 名受试者。安全性方面，Rocatinlimab 组与安慰剂组治疗期间不良事件发生率总体相近，前者最常见的不良事件包括发热、寒战和口腔溃疡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202175112a6c9d457&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202175112a6c9d457&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4566","LU1061106388.HKD","LU2242646821.SGD","LU1571399168.USD","LU2468319806.SGD","BK4588","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0058720904.USD","BK4533","LU1057294990.SGD","IE0009355771.USD","LU0109394709.USD","BK4581","LU0868494617.USD","LU1023059063.AUD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","AMGN","BK4585","LU1983299246.USD","BK4534","BK4599","BK4139","IE0002141913.USD","LU0289739699.SGD","LU0889565916.HKD","LU0122379950.USD","SG9999001440.SGD","LU2089984988.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU2112291526.USD","LU2242652126.USD"],"gpt_icon":0},{"id":"2607090010","title":"奥本海默上调安进目标价至400美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607090010","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607090010?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:55","pubTimestamp":1769763325,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4581","LU0868494617.USD","LU0122379950.USD","BK4588","LU0320765992.SGD","LU1057294990.SGD","BK4599","LU2242646821.SGD","BK4534","LU2089984988.USD","IE00B4R5TH58.HKD","LU0289739699.SGD","BK4585","IE0009355771.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","LU2112291526.USD","IE00BJJMRZ35.SGD","SG9999001440.SGD","LU0058720904.USD","IE0002141913.USD","IE00BJT1NW94.SGD","BK4566","LU0109394709.USD","LU1983299246.USD","IE00B2B36J28.USD","LU2242652126.USD","LU1571399168.USD","LU2468319806.SGD","LU0889565916.HKD","BK4139","BK4533","AMGN","LU1061106388.HKD"],"gpt_icon":0},{"id":"2606728962","title":"瑞银上调安进目标价至390美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606728962","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606728962?lang=zh_cn&edition=full","pubTime":"2026-01-27 12:27","pubTimestamp":1769488022,"startTime":"0","endTime":"0","summary":"瑞银将安进的目标价从380美元上调至390美元，维持“买入”评级。(格隆汇)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260127/31975225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["AMGN"],"gpt_icon":0},{"id":"1172625763","title":"减肥药进入“长期维持+低频注射”时代，安进“月服”优势引领千亿美元市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1172625763","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172625763?lang=zh_cn&edition=full","pubTime":"2026-01-14 15:12","pubTimestamp":1768374763,"startTime":"0","endTime":"0","summary":"高盛认为在“下一代减肥药物” MariTide相关的重大催化之下，安进有望踏上价值重估轨迹，其股价上行空间相比于同行可能更加广阔。全球肥胖率持续上升，肥胖被认为是重大慢性疾病风险因素，导致对有效减重治疗的巨大需求持续扩大。随着价格下降和医保覆盖扩大，患者用药意愿和人数预计大幅提升，这将推动市场规模增长。","market":"us","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1392679.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"减肥药进入“长期维持+低频注射”时代，安进“月服”优势引领千亿美元市场","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4566","LU1061106388.HKD","LU2242646821.SGD","LU1571399168.USD","LU2468319806.SGD","BK4588","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0058720904.USD","BK4533","LU1057294990.SGD","IE0009355771.USD","LU0109394709.USD","BK4581","LU0868494617.USD","LU1023059063.AUD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","AMGN","BK4585","LU1983299246.USD","BK4534","BK4599","BK4139","IE0002141913.USD","LU0289739699.SGD","LU0889565916.HKD","LU0122379950.USD","SG9999001440.SGD","LU2089984988.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU2112291526.USD","LU2242652126.USD"],"gpt_icon":0},{"id":"2603674356","title":"减肥药进入“长期维持+低频注射”时代 安进(AMGN.US)“月服”优势引领千亿美元市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2603674356","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603674356?lang=zh_cn&edition=full","pubTime":"2026-01-14 14:57","pubTimestamp":1768373853,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国大型制药/生物科技巨头安进公司当地时间周一透露，其试验性的减肥药——即有着“下一代减肥药”称号的GLP-1相关联药物MariTide的一项最新临床试验结果显示，当肥胖症患者们每月仅仅注射一次时，他们能够在两年内稳定保持体重下降趋势。随着价格下降和医保覆盖扩大，患者用药意愿和人数预计大幅提升，这将推动市场规模增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392679.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"减肥药进入“长期维持+低频注射”时代 安进(AMGN.US)“月服”优势引领千亿美元市场","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1061106388.HKD","LU0889565916.HKD","LU2089984988.USD","LU2242652126.USD","IE00B4R5TH58.HKD","LU1983299246.USD","LU0289739699.SGD","BK4139","LU2242646821.SGD","LU0122379950.USD","LU1057294990.SGD","LU1023059063.AUD","LU1571399168.USD","SG9999001440.SGD","BK4533","BK4599","BK4585","LU2112291526.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","BK4534","BK4581","IE0002141913.USD","AMGN","IE00B2B36J28.USD","BK4566","LU2468319806.SGD","LU0320765992.SGD","IE0009355771.USD","LU0868494617.USD","BK4588","IE00BFTCPJ56.SGD","LU0058720904.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"1148445500","title":"安进：Maritide扩展研究52周数据显示，绝大多数受试者采用较低月剂量或季度剂量后维持二期试验第一阶段减重效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1148445500","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148445500?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:53","pubTimestamp":1768262001,"startTime":"0","endTime":"0","summary":"安进公司最新公布的Maritide扩展研究结果显示，在为期52周的延长试验期间，绝大多数接受较低月度剂量或季度剂量给药的参与者，成功维持了在二期临床试验第一阶段所达到的体重减轻效果。这项扩展研究旨在评估不同给药方案对体重维持的长期影响，初步数据表明药物在延长用药周期后仍能保持疗效稳定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE0002141913.USD","LU0109394709.USD","BK4599","BK4581","LU0868494617.USD","BK4533","BK4139","LU2242646821.SGD","SG9999001440.SGD","BK4585","LU0889565916.HKD","BK4534","LU2112291526.USD","IE0009355771.USD","LU1057294990.SGD","IE00BFTCPJ56.SGD","LU0289739699.SGD","LU0122379950.USD","IE00B2B36J28.USD","LU1571399168.USD","AMGN","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU1983299246.USD","LU1061106388.HKD","BK4588","BK4566","LU2468319806.SGD","LU2089984988.USD","LU1023059063.AUD","LU2242652126.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"1117228263","title":"安进：Maritide治疗第二年耐受性良好，季度剂量方案下恶心呕吐发生率极低且无新增安全信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1117228263","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117228263?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:53","pubTimestamp":1768261997,"startTime":"0","endTime":"0","summary":"安进公司最新研究数据显示，其药物Maritide在第二年治疗期间展现出优异的耐受性特征。值得注意的是，即便是采用季度给药方案，患者的不良反应发生率仍维持在极低水平。\n临床观察表明，治疗组恶心和呕吐等胃肠道不良事件的发生率显著偏低。更关键的是，在整个第二年研究周期内，未监测到任何新的安全性信号，这进一步印证了该疗法的可靠性和安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","BK4533","BK4566","SG9999001440.SGD","BK4585","LU0289739699.SGD","LU0109394709.USD","LU0868494617.USD","LU0889565916.HKD","BK4599","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU2468319806.SGD","AMGN","LU2242652126.USD","IE00B2B36J28.USD","LU2089984988.USD","BK4534","IE00BFTCPJ56.SGD","LU1571399168.USD","LU1023059063.AUD","LU0320765992.SGD","IE0002141913.USD","LU2112291526.USD","LU1057294990.SGD","LU0122379950.USD","BK4588","IE0009355771.USD","LU1061106388.HKD","LU1983299246.USD","BK4581","LU0058720904.USD","IE00B4R5TH58.HKD","BK4139"],"gpt_icon":0},{"id":"1139121916","title":"安进：每月注射马利肽的24周研究显示2型糖尿病患者糖化血红蛋白与体重均现强劲且具临床意义的下降","url":"https://stock-news.laohu8.com/highlight/detail?id=1139121916","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139121916?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:50","pubTimestamp":1768261815,"startTime":"0","endTime":"0","summary":"安进公司公布的一项为期24周的研究结果显示，在2型糖尿病患者中，每月注射一次马利肽（Maritide）能够显著且具有临床意义地降低患者的糖化血红蛋白（HbA1c）水平和体重。该研究数据展现出积极的治疗效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","LU0889565916.HKD","LU2089984988.USD","LU2242652126.USD","IE00B4R5TH58.HKD","LU1983299246.USD","LU0289739699.SGD","BK4139","LU2242646821.SGD","LU0122379950.USD","LU1057294990.SGD","LU1023059063.AUD","LU1571399168.USD","SG9999001440.SGD","BK4533","BK4599","BK4585","LU2112291526.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","BK4534","BK4581","IE0002141913.USD","AMGN","IE00B2B36J28.USD","BK4566","LU2468319806.SGD","LU0320765992.SGD","IE0009355771.USD","LU0868494617.USD","BK4588","IE00BFTCPJ56.SGD","LU0058720904.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2601235804","title":"美股异动丨减肥药概念股上涨，礼来涨超5%创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2601235804","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601235804?lang=zh_cn&edition=full","pubTime":"2026-01-07 23:18","pubTimestamp":1767799100,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b2662d3ff1dff9c19973bc9c47bc6f94","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0256863811.USD","IE0005OL40V9.USD","LU0823416689.USD","LU2361045086.USD","LU2211815571.USD","LU2462157665.USD","LU2237443622.USD","LU0203201768.USD","LU1267930730.SGD","LU1868836757.USD","SG9999001176.SGD","LU1548497426.USD","LU2552382132.HKD","IE00BK4W5M84.HKD","LU2471134523.USD","IE00B1BXHZ80.USD","LU0471298694.HKD","IE0002141913.USD","LU0122379950.USD","LU1127390331.HKD","BK4516","BK4007","LU2357305700.SGD","LU0256863902.USD","LU2112291526.USD","LU2361044865.SGD","LLY","LU1804176565.USD","BK4534","LU0079474960.USD","SG9999001176.USD","LU0787776722.HKD","LU0320765992.SGD","LU1093756168.USD","IE00BKPKM429.USD","LU0432979614.USD","LU1623119135.USD","LU1917777945.USD","LU0289739699.SGD","LU2491050071.SGD","IE00BK4W5L77.USD","LU0471298777.SGD","LU2168564222.USD","LU2237438978.USD","LU0234572021.USD","IE00BJT1NW94.SGD","LU1061106388.HKD","LU0882574055.USD","LU1023059063.AUD","SG9999015945.SGD","LU2552382058.USD","LU2471134796.USD","LU0266013472.USD","GB00BDT5M118.USD","LU1057294990.SGD","IE00BKDWB100.SGD","LU2552382215.SGD","RHHBY","LU0097036916.USD","LU1868837136.USD","LU1868836914.USD","LU1868837300.USD","AMGN","IE0004445239.USD","LU0061475181.USD","LU1366192091.USD","LU2168564495.EUR","LU1093756325.SGD","IE00B7KXQ091.USD","LU1983299246.USD","IE00BWXC8680.SGD","BK4581","LU2746668974.SGD","BK4533","LU0094547139.USD","IE00B2B36J28.USD","LU2063271972.USD","LU0943347566.SGD","IE0009355771.USD","LU0889565916.HKD","LU0006306889.USD","LU0203202063.USD","NVO","LU0823434583.USD","LU0316494557.USD","SG9999014880.SGD","SGXZ57979304.SGD","LU0353189680.USD","LU0106261372.USD","LU2237443895.HKD","LU1988902786.USD","IE00B1XK9C88.USD","SG9999014914.USD","LU0198837287.USD","IE00BN29S564.USD","SG9999015986.USD","LU0820561909.HKD","LU1712237335.SGD","LU2265009873.SGD","SG9999013999.USD","IE00B4R5TH58.HKD","LU2461242641.AUD","IE00BJJMRZ35.SGD","SG9999018857.SGD","LU0238689110.USD","LU0320765059.SGD","LU0466842654.USD","SG9999018865.SGD","SGXZ99366536.SGD","LU2108987350.USD","IE00BJLML261.HKD","IE0004445015.USD","LU1814569148.SGD","LU2237443382.USD","LU2750360997.AUD","BK4599","LU2236285917.USD","LU0820561818.USD","SG9999017495.SGD","BK4588","LU2361044949.HKD","IE00B775H168.HKD","LU2746668461.USD","SG9999015952.SGD","LU0823434740.USD","LU2471134879.HKD","LU0385154629.USD","LU2237443549.SGD","LU1291159041.SGD","LU0683600562.USD","LU0354030438.USD","LU0109391861.USD","LU0323591593.USD","IE00BFSS8Q28.SGD","LU2360106947.USD","LU0882574139.USD","LU2471134952.CNY","LU1989771016.USD","LU1232071149.USD","LU0456855351.SGD","LU1280957306.USD","LU2324357040.USD","LU0353189763.USD","LU1069344957.HKD","LU2602419157.SGD","SGXZ31699556.SGD","LU1035775433.USD","LU2237443465.HKD","SG9999014898.SGD","SG9999014906.USD","LU1323610961.USD","IE00BJJMRY28.SGD","LU2168563687.JPY","IE00BFSS7M15.SGD","LU1064131342.USD","LU1551013425.SGD","SGXZ81514606.USD","SGXZ51526630.SGD","LU0672654240.SGD","LU0708995401.HKD","LU2491050154.USD","LU0354030511.USD","LU0786609619.USD","04332","LU2023250504.SGD","LU2456880835.USD","LU2468319806.SGD","LU1720051108.HKD","BK4585","LU2087625088.SGD","IE00BJJMRX11.SGD","LU2417539215.USD","IE00BFTCPJ56.SGD","LU0058720904.USD","LU0417517546.SGD","LU0689472784.USD","LU2089984988.USD","LU2106854487.HKD","LU2237443978.SGD","LU1720051017.SGD","LU1868836591.USD","SG9999015978.USD","LU2168564065.EUR","LU1551013342.USD","LU2264538146.SGD","LU1974910355.USD","LU0109394709.USD","LU2750360641.GBP","LU0096364046.USD","IE00B4JS1V06.HKD","LU2168564149.EUR","LU2491049909.HKD","LU0114720955.EUR","LU0640476718.USD"],"gpt_icon":0},{"id":"1154969640","title":"美股减肥药概念走高！礼来涨超4%，股价创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=1154969640","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154969640?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:47","pubTimestamp":1767797235,"startTime":"0","endTime":"0","summary":"1月7日，美股减肥药概念走高，$礼来(LLY)$涨超4%，股价创历史新高；$安进(AMGN)$涨超3%，$诺和诺德(NVO)$、$辉瑞(PFE)$涨超1%。","market":"us","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b2662d3ff1dff9c19973bc9c47bc6f94","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","NVO","AMGN"],"gpt_icon":0},{"id":"1171276942","title":"Disco制药公司：有望获得最高6.18亿美元潜在交易总额及销售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=1171276942","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171276942?lang=zh_cn&edition=full","pubTime":"2026-01-07 18:10","pubTimestamp":1767780610,"startTime":"0","endTime":"0","summary":"根据最新合作协议条款，生物科技企业Disco制药公司将有机会获得总额高达6.18亿美元的阶段性付款。该协议还包含未来产品销售的分成权益，标志着公司创新药物研发平台获得市场认可。此次交易涉及多个靶向疗法的开发权益，资金将分阶段与研发里程碑挂钩支付。业内观察人士指出，这种结构化合作模式既保障了初创企业的现金流，又为合作方控制了研发风险。随着基因编辑技术的快速发展，此类高价值合作正在重塑生物制药行业的创新生态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","BK4566","IE00B2B36J28.USD","LU2242652126.USD","LU1023059063.AUD","BK4533","BK4534","LU1571399168.USD","BK4139","LU2242646821.SGD","LU2112291526.USD","IE0002141913.USD","IE0009355771.USD","LU0058720904.USD","LU0889565916.HKD","LU2468319806.SGD","SG9999001440.SGD","BK4588","LU0320765992.SGD","LU1983299246.USD","IE00BJT1NW94.SGD","LU1061106388.HKD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0122379950.USD","LU2089984988.USD","BK4585","LU0109394709.USD","AMGN","LU1057294990.SGD","BK4599","BK4581","LU0868494617.USD"],"gpt_icon":0},{"id":"1196601499","title":"Disco Pharmaceuticals与安进达成许可协议 共同推进新型癌症表面组靶向疗法研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1196601499","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196601499?lang=zh_cn&edition=full","pubTime":"2026-01-07 18:09","pubTimestamp":1767780543,"startTime":"0","endTime":"0","summary":"生物技术公司Disco Pharmaceuticals近日宣布与全球生物制药巨头安进（Amgen）签署一项重要许可协议。该合作旨在加速开发针对癌症表面组的新型靶向疗法，通过整合双方在肿瘤免疫学和药物研发领域的专长，探索创新治疗途径。此次合作有望为癌症患者带来更精准、有效的治疗方案，标志着表面组学研究在临床转化领域迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","IE00B4R5TH58.HKD","BK4139","IE00BJJMRZ35.SGD","LU1057294990.SGD","BK4566","AMGN","BK4599","LU2468319806.SGD","BK4585","LU1571399168.USD","SG9999001440.SGD","BK4588","LU1983299246.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0058720904.USD","BK4581","LU0122379950.USD","LU1061106388.HKD","LU2242652126.USD","LU2089984988.USD","BK4533","IE00B2B36J28.USD","LU2112291526.USD","IE0009355771.USD","LU0889565916.HKD","BK4534","LU0320765992.SGD","LU0109394709.USD","LU0289739699.SGD","LU0868494617.USD","LU2242646821.SGD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2601822994","title":"瑞银看高安进(AMGN.US)至380美元：两款在研药物有望驱动增长至2030年","url":"https://stock-news.laohu8.com/highlight/detail?id=2601822994","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601822994?lang=zh_cn&edition=full","pubTime":"2026-01-07 14:56","pubTimestamp":1767768985,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银将其对美国生物科技巨头安进的股票评级由“中性”上调至“买入”，目标价由317美元上调至380美元，称其两款处于研发后期的产品——减肥药MariTide和心血管药物olpasiran——将驱动公司增长至2030年。这一目标价较安进周二美股收盘价有近15%的上行空间。数据显示，未合并2型糖尿病的肥胖/超重患者通过该药物治疗52周后，平均减重达20%，且未出现减重平台期;合并2型糖尿病的患者平均减重17%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞银看高安进(AMGN.US)至380美元：两款在研药物有望驱动增长至2030年","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1983299246.USD","LU2112291526.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","BK4599","LU0320765992.SGD","LU0109394709.USD","LU0868494617.USD","AMGN","LU2089984988.USD","LU1057294990.SGD","IE00B4R5TH58.HKD","LU0289739699.SGD","SG9999001440.SGD","LU1023059063.AUD","IE00BJJMRZ35.SGD","BK4581","LU1061106388.HKD","LU2242652126.USD","IE00B2B36J28.USD","BK4534","LU1571399168.USD","BK4585","IE0009355771.USD","LU0058720904.USD","BK4566","BK4139","BK4533","LU2468319806.SGD","LU2242646821.SGD","IE0002141913.USD","BK4588","IE00BJT1NW94.SGD","LU0122379950.USD"],"gpt_icon":0},{"id":"2595440607","title":"Argus上调安进目标价至360美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595440607","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595440607?lang=zh_cn&edition=full","pubTime":"2025-12-31 10:22","pubTimestamp":1767147767,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["AMGN","BK4139","LU1983299246.USD","LU0058720904.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU0320765992.SGD","LU1023059063.AUD","BK4599","LU1061106388.HKD","IE00B4R5TH58.HKD","LU0889565916.HKD","LU1057294990.SGD","LU0289739699.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU2242646821.SGD","LU0122379950.USD","BK4588","BK4533","LU0868494617.USD","BK4581","LU0109394709.USD","LU2468319806.SGD","SG9999001440.SGD","BK4534","LU2242652126.USD","LU2089984988.USD","IE00BJT1NW94.SGD","BK4585","LU1571399168.USD","LU2112291526.USD","BK4566"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amgen.com","stockEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.1292},{"period":"3month","weight":0.0875},{"period":"6month","weight":0.2352},{"period":"1year","weight":0.2411},{"period":"ytd","weight":0.1188}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":-0.018},{"period":"3month","weight":0.0139},{"period":"6month","weight":0.0588},{"period":"1year","weight":0.1291},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Amgen Inc是一家生物技术公司。该公司从事发现、开发、生产和提供治疗最棘手疾病的药物。该公司专注于医疗需求尚未得到满足的领域，并利用专业知识努力寻求改善人们生活的解决方案。该公司在人类治疗领域开展业务。该公司的营销产品组合包括EPOGEN（阿法依泊汀）、Aranesp（阿法达贝泊汀）、Parsabiv（etelcalcetide）、Neulasta（培非格司亭）；KANJINTI（曲妥珠单抗）、Otezla、BLINCYTO（blinatumomab）、ACTIMMUNE（干扰素γ-1b）、Neulasta（培非格司亭）、Sensipar/Mimpara（西那卡塞）、Prolia（地舒单抗）、ENBREL、QUINSAIR（左氧氟沙星）、Repatha（依洛尤单抗）等。该公司在美国和加拿大销售肿瘤坏死因子阻断剂ENBREL。该公司在全球许多国家销售抑制磷酸二酯酶4的小分子药物Otezla。该公司在全球许多国家销售前蛋白转化酶枯草溶菌素/kexin 9型 (PCSK9) 抑制剂Repatha。","yearOnYearQuotes":[{"month":1,"riseRate":0.651163,"avgChangeRate":0.034336},{"month":2,"riseRate":0.488372,"avgChangeRate":0.000526},{"month":3,"riseRate":0.52381,"avgChangeRate":0.019224},{"month":4,"riseRate":0.452381,"avgChangeRate":-0.002852},{"month":5,"riseRate":0.52381,"avgChangeRate":0.024179},{"month":6,"riseRate":0.5,"avgChangeRate":0.003875},{"month":7,"riseRate":0.767442,"avgChangeRate":0.052562},{"month":8,"riseRate":0.604651,"avgChangeRate":0.004451},{"month":9,"riseRate":0.511628,"avgChangeRate":0.002296},{"month":10,"riseRate":0.534884,"avgChangeRate":0.021538},{"month":11,"riseRate":0.627907,"avgChangeRate":0.022348},{"month":12,"riseRate":0.627907,"avgChangeRate":0.045446}],"exchange":"NASDAQ","name":"安进","nameEN":"Amgen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安进,AMGN,安进股票,安进股票老虎,安进股票老虎国际,安进行情,安进股票行情,安进股价,安进股市,安进股票价格,安进股票交易,安进股票购买,安进股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}